Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has issued an announcement.
Recordati has appointed Mike McClellan as the new Chief Financial Officer, effective January 1, 2026. McClellan brings nearly 30 years of experience in the pharmaceutical sector, having contributed to significant growth and profitability at Almirall, Teva, and Sanofi. His expertise is expected to support Recordati’s strategy of continuous growth and business development, ensuring a smooth transition and furthering the company’s reputation in the industry.
The most recent analyst rating on (IT:REC) stock is a Sell with a EUR50.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati is an international pharmaceutical group with Italian roots, listed on the Italian Stock Exchange. The company provides therapeutic options in specialty and general medicine, as well as rare diseases, operating in a fully integrated manner from clinical development to marketing across 150 countries in the EMEA, Americas, and APAC regions.
Average Trading Volume: 241,749
Technical Sentiment Signal: Buy
Current Market Cap: €10.55B
See more data about REC stock on TipRanks’ Stock Analysis page.